国内精品久久久久伊人aⅴ,日韩中文字幕一区,黄视频网站在线观看

a级一a一级在线观看_a级在线观看视频_a极毛片_a毛片_全部免费毛片在线播放_全部孕妇丰满孕妇孕交


        »ñµÃ»ý·Ö
        ×ÊÁÏ¿â»áÔ±µÇ¼
        ËÑË÷: [¸ß¼¶ËÑË÷]
        ÏÂÔØÊ×Ò³ | ×ÊÔ´·ÖÀà | ÏÂÔØÅÅÐÐ
        ÄúµÄλÖÃ: Ê×Ò³ > ±ê×¼Îĵµ  > ÆäËü±ê×¼
         
        ·ÖÀർº½
        ÏÂÔØÅÅÐÐ
        ×îÐÂ×ÊÔ´
        ¹Û²âÖ¸±ê±êʶ·ûÂß¼­ÃüÃûÓë±àÂëϵͳLOINCÓû§Ö¸ÄÏÖÐÎİæ
        ×ÊÔ´´óС£º1.59 MB ×ÊÔ´ÀàÐÍ£ºÎĵµ
        ÏÂÔØ»ý·Ö£º 90
        ¸ü¶à
        -->
        ÏÂÔØÍ³¼Æ£º×ÜÏÂÔØ£º0£¬±¾ÔÂÏÂÔØ£º0£¬±¾ÖÜÏÂÔØ£º0£¬½ñÈÕÏÂÔØ£º0
        ·¢±íÆÀÂÛ ´íÎó±¨¸æ ¼ÓÈëÊղؼÐ
        ×ÊÔ´½éÉÜ
        Ŀ¼£¨Table of Contents£©
        °æÈ¨ÉùÃ÷ÓëÐí¿ÉЭÒ飨COPYRIGHT NOTICE AND LICENSE£©.............................................................................6
        ǰÑÔÓë¼ò½é£¨PREFACE AND INTRODUCTION£©...................................................................................................12
        ÖÂл£¨ACKNOWLEDGMENTS£©................................................................................................................................17
        1 Ä¿±ê£¨GOALS£©...........................................................................................................................................................18
        1.1 ³É¹¦Ó¦Óã¨SUCCESSES£©........................................................................................................................................19
        1.2 ²»ÊôÓÚLOINCÃû³Æ×é³É²¿·ÖµÄÄÚÈÝ£¨WHAT IS NOT PART OF THE NAME£©........................................................20
        1.3 ±¾Ö¸ÄϵÄÊÊÓ÷¶Î§£¨SCOPE OF THIS DOCUMENT£©................................................................................................21
        2 ÊÔÑé/¹Û²âÖ¸±êÃû³ÆµÄÖ÷Òª×é³É²¿·Ö£¨MAJOR "PARTS" OF A TEST/OBSERVATION NAME£©..................22
        2.1 Ò»°ãÃüÃû¹æÔò£¨GENERAL NAMING CONVENTIONS£©.............................................................................................23
        2.1.1 ³É·Ö/·ÖÎöÎïÃû³ÆÖеÄËõÂÔÓAbbreviations in names of component/analyte£©.........................................23
        2.1.2 È«³ÆÖгɷ֣¨·ÖÎöÎ²¿·ÖµÄÒ»°ãÃüÃû¹æÔò£ÛGeneral naming rules for the component (analyte) part of the fully specified name£Ý...23
        2.1.3 ·ÖÎöÎïÃû³ÆÖеıêµã·ûºÅ£¨Punctuation in analyte names£©.........................................................................25
        2.1.4 ×Öĸ²»Çø·Ö´óСд£¨Case insensitivity£©........................................................................................................25
        2.1.5 ÂÞÂíÊý×ÖÓë°¢À­²®Êý×Ö£¨Roman numerals vs. Arabic numerals£©................................................................25
        2.2 ³É·Ö/·ÖÎöÎµÚÒ»²¿·Ö£©£ÛCOMPONENT/ANALYTE (1ST PART)£Ý......................................................................25
        2.2.1 ·ÖÎöÎïÃû³Æ£¨µÚÒ»×ӿ飩£ÛAnalyte Name (1st subpart)£Ý............................................................................26
        2.2.2 ´Ì¼¤ÊÔÑ飨µÚ¶þ×ӿ飩£ÛChallenge test (2nd subpart)£Ý...............................................................................26
        2.3 ÊôÐÔÀàÐÍ£¨ÓÖ³ÆÁ¿ÖµÀàÐÍ£©£¨µÚ¶þ²¿·Ö£©£ÛKIND OF PROPERTY (ALSO CALLED KIND OF QUANTITY) (2ND PART)£Ý..32
        2.4 ʱ¼äÌØÕ÷£¨Ê±¿ÌÓëʱ¼ä¼ä¸ô£©£¨µÚÈý²¿·Ö£©£ÛTIME ASPECT (POINT OR MOMENT IN TIME VS. TIME INTERVAL) (3RD PART)£Ý35
        2.4.1 ʱ¼äÌØÕ÷µÄÐÞÊγɷ֣¨Time Aspect Modifier£©............................................................................................37
        2.5 Ìåϵ£¨Ñù±¾£©ÀàÐÍ£¨µÚËIJ¿·Ö£©£ÛSYSTEM (SAMPLE) TYPE (4TH PART)£Ý........................................................37
        2.5.1 ³¬Ìåϵ£¨µÚ¶þ×ӿ飩£ÛSuper system (2nd subpart)£Ý....................................................................................39
        2.6 ±ê³ßÀàÐÍ£¨µÚÎ岿·Ö£©£ÛTYPE OF SCALE (5TH PART)£Ý.......................................................................................41
        2.7 ·½·¨ÀàÐÍ£¨µÚÁù²¿·Ö£©£ÛTYPE OF METHOD (6TH PART)£Ý...................................................................................42
        2.7.1 DNA/RNA̽Õë/Ö¸±ê£¨DNA/RNA probes/measures£©..................................................................................43
        2.7.2 ÃâÒßÓ«¹â£¨IF£©£ÛImmune fluorescence (IF)£Ý...............................................................................................44
        2.7.3 ÃâÒßȾɫ£¨Immune Stain£©.............................................................................................................................44
        2.7.4 øÃâÒß·ÖÎö£¨EIA£©£ÛEnzyme Immune Assay (EIA)£Ý.................................................................................44
        2.7.5 ÄýѪ¹¦ÄÜÊÔÑ飨Coagulation£©........................................................................................................................44
        2.7.6 ȾɫÊÔÑé¼ì²é£¨Stains£©..................................................................................................................................44
        2.7.7 ÁÙ´²Ö¸±ê£¨Clinical measures£©.......................................................................................................................44
        2.7.8 ³ÉÏñ¼ì²é£¨Imaging studies£©...........................................................................................................................45
        2.8 ¶ÌСʵÓõļò³Æ£¨SHORT CONVENIENT NAMES£©..................................................................................................45
        3 ÌØÊâÇé¿ö£¨SPECIAL CASES£©..................................................................................................................................45
        3.1 ±»¿´×÷±äÁ¿»òÊýÖµµÄ½á¹û£¨FINDINGS VIEWED AS VARIABLES OR AS VALUES£©..................................................45
        3.1.1 ½á¹ûȡֵ£¨Value£©..........................................................................................................................................45
        3.1.2 ¿É±äÐÔ»ò¶àÏîÑ¡ÔñÐÔ½á¹ûµÄ±êʶ·½·¨£ÛVariable (Multiple Choice) Approach£Ý........................................46
        3.2 Ѫ¿â£¨BLOOD BANK£©.............................................................................................................................................46
        3.3 ÃâÒß»îÐÔ¼ì²é£¨Á÷ʽϸ°ûÒÇ£©£ÛIMMUNOCOMPETENCE STUDIES (FLOW CYTOMETRY)£Ý...................................47
        3.4 ΢ÉúÎïѧ½á¹ûµÄÒ»°ã´¦Àí·½·¨£¨GENERAL APPROACH TO MICROBIOLOGY RESULTS£©.......................................48
        3.5 ¿¹ÉúËØÃô¸ÐÐÔÊÔÑ飨ANTIMICROBIAL SUSCEPTIBILITIES£©...................................................................................50
        3.6 ϸ°û¼ÆÊý£¨CELL COUNTS£©....................................................................................................................................50
        3.7 Ƥ·ôÊÔÑ飨SKIN TESTS£©........................................................................................................................................51
        3.8 ¶¾Àíѧ¡ªÒ©ÎïÀÄÓõÄɸ²éÓëÈ·ÈÏ£¨TOXICOLOGY ¨C DRUG OF ABUSE SCREENING AND CONFIRMATION£©.........51
        3.8.1 Ò©ÎïµÄ¶¾Àíѧ·Ö×飨Toxicology drug groups£©.............................................................................................52
        3.8.2 ÅжϽçÖµ£¨Cutoffs£©........................................................................................................................................53
        LOINC Users¡¯ Guide translated to Simplified Chinese ¡ªJune 1, 2005
        4
        3.8.3 ɸ²éÓëÈ·ÈÏ·½·¨µÄ±¨¸æ£¨Reporting the method used for screen and confirm£©............................................53
        3.8.4 ¾ßÌåÒ©Îï/´úлÎïµÄ¼ì²â½á¹û£¨Individual drug/metabolite test results£©......................................................54
        3.8.5 ÃüÃûÎÊÌ⣨Naming issues£©.............................................................................................................................54
        3.8.6 С½á£¨Summary£©............................................................................................................................................54
        3.9 ·Ö×ÓÒÅ´«Ñ§·½ÃæµÄLOINCÃüÃû£¨MOLECULAR GENETICS LOINC NAMING£©...................................................55
        3.9.1 ÒýÑÔ£¨Introduction£©........................................................................................................................................55
        3.9.2 ÊõÓïѧ£¨Terminology£©...................................................................................................................................55
        3.9.3 ·Ö×ÓÒÅ´«Ñ§Ò»°ãÃüÃû¹æÔò£¨General Molecular genetic naming rules£©........................................................56
        3.9.4 ´«È¾ÐÔ¼²²¡£¨Infectious Diseases£©.................................................................................................................57
        3.9.5 ÒÅ´«ÐÔ¼²²¡£¨Genetic Diseases£©.....................................................................................................................57
        3.9.6 ÈýºËÜÕËáÖØ¸´ÐòÁУ¨Trinucleotide repeats£©..................................................................................................59
        3.9.7 ѪҺ²¡Àíѧ»ùÒòÖØ×飨Hematopathology gene re-arrangement£©.................................................................59
        3.9.8 »ùÒòÒ×루Translocations£©............................................................................................................................60
        3.9.9 Éí·Ý²âÊÔ£¨Identity testing£©............................................................................................................................60
        3.9.10 Ö×ÁöÏà¹ØµÄÖ×ÁöÒÅ´«Ñ§£¨Tumor Relation Tumor Genetics£©......................................................................61
        3.10 ±ä̬·´Ó¦µÄ¼ì²â£¨ALLERGY TESTING£©..............................................................................................................62
        4 ÁÙ´²¹Û²âÖ¸±ê£¨CLINICAL OBSERVATIONS AND MEASURES£©....................................................................62
        4.1 ÒýÑÔ£¨INTRODUCTION£©..........................................................................................................................................63
        4.2 Ô­×ÓÐÍÓë·Ö×ÓÐÍ£¨Ç°×éºÏʽÃüÃû£©[ATOMIC VERSUS MOLECULAR (PRE-COORDINATED NAMES)]..........................................65
        4.3 ·ÅÉäҽѧ±¨¸æ£¨RADIOLOGY REPORTS£©...............................................................................................................65
        4.3.1 Õï¶ÏÐÔ·ÅÉäҽѧ±¨¸æ£¨Diagnostic Radiology Reports£©.........................................................................66
        4.3.2 ½éÈëÐÔ·ÅÉäҽѧ±¨¸æ£¨Interventional Radiology Reports£©..........................................................................69
        5 Ö×ÁöµÇ¼Ç£¨TUMOR REGISTRY£©............................................................................................................................70
        6 Ë÷ÅâÐÅÏ¢¸½¼þ£¨CLAIMS ATTACHMENTS£©.........................................................................................................70
        7 HL7 LOINCÎĵµÀàÐʹʱíÓò£¨HL7 LOINC DOCUMENT TYPE VOCABULARY DOMAIN£©.....................70
        7.1 ÎĵµÀàÐÍ´úÂëÔÚHL7ÏûÏ¢ÖеÄʹÓã¨USE OF DOCUMENT TYPE CODES IN HL7 MESSAGES£©............................70
        7.2 ÓëÆäËüÊõÓïµÄ¹ØÏµ£¨RELATIONSHIP WITH OTHER TERMINOLOGIES£©...................................................................71
        7.3 ÎĵµÀàÐÍ×é¼þ£¨DOCUMENT TYPE COMPONENTS£©...............................................................................................71
        7.4 ²ÉÓöà¸ö×é¼þ´´½¨ÁÙ´²¼Ç¼µÄ¹æÔò£¨RULES FOR CREATING CLINICAL NOTES FROM MULTIPLE COMPONENTS£©........74
        7.5 ¹¤×÷Õ¹Íû£¨FUTURE WORK£©..................................................................................................................................75
        8 Ò½Öö×飨ORDER PANELS£¯BATTERIES£©...........................................................................................................81
        8.1 Ä¿µÄ£¨GOALS£©.......................................................................................................................................................82
        8.2 ¼¶ÁªÊÔÑ飨REFLEX TESTS£¬×·¼ÓÊÔÑ飩................................................................................................................83
        8.3 ¼ÆËã»òÑÜÉú½á¹û£¨CALCULATED OR DERIVED RESULTS£©.....................................................................................83
        8.4 ¹ØÁª¹Û²âÖ¸±ê£¨ASSOCIATED OBSERVATIONS£©.....................................................................................................83
        8.5 Ò½Öö×éµÄLOINCÃüÃû¹æÔò£¨LOINC RULES FOR REPRESENTING ORDER PANEL NAMES£©..................................83
        9 ±ê×¼»¯µ÷²éÎÊ¾í£¨STANDARDIZED SURVEY INSTRUMENTS£©......................................................................85
        ¸½Â¼£¨APPENDICES£©...................................................................................................................................................86
        ¸½Â¼A¡ªLOINCÊý¾Ý¿â½á¹¹£¨APPENDIX A - LOINC DATABASE STRUCTURE£©.......................................86
        ¸½Â¼B¡ªÀࣨAPPENDIX B ¨C CLASSES£©.............................................................................................................90
        ¸½Â¼C¡ªMOD 10ģУÑéλµÄ¼ÆËã·½·¨£¨APPENDIX C - CALCULATING MOD 10 CHECK DIGITS£©........93
        ¸½Â¼D¡ªÏòLOINCÊý¾Ý¿âÌá½»ÐÂÔö»ò±ä¸ü¼Ç¼µÄ·½·¨Óë²½Ö裨APPENDIX D - PROCEDURE FOR SUBMITTING ADDITIONS/CHANGES TO THE DATABASE£©..................................94
        ¸½Â¼E¡ªÓйØLOINC´òÓ¡±¨¸æµÄ˵Ã÷£¨APPENDIX E - LOINC PRINTED REPORT DESCRIPTION£©......116
        ¸½Â¼F¡ªLOINCÊôÐÔÆ¥ÅäʾÀý£¨APPENDIX F - EXAMPLES FOR LOINC PROPERTY MATCHING£©......117
        ¸½Â¼G¡ªLOINCίԱ»á³ÉÔ±Ãûµ¥£¨APPENDIX G - LOINC COMMITTEE MEMBERS£©..............................122
        ²Î¿¼ÎÄÏ×£¨LITERATURE CITED£©..........................................................................................................................124
        LOINC Users¡¯ Guide translated to Simplified Chinese ¡ªJune 1, 2005
        5
        ±í£¨Tables£©
        ±í1. ·ÖÎöÎïÈ«³ÆµÄ²ã¼¶½á¹¹£¨Table 1: Hierarchical Structure of Fully Specified Analyte Names£©...................................................22
        ±í2. ³É·Ö£¨·ÖÎöÎÃû³ÆÖÐÔÊÐí³öÏÖµÄËõÂÔÓTable 2: Allowable Abbreviations in Component (analyte) Names£©...................23
        ±í3. ×Öĸ´óСд¹æÔò£¨Table 3: Case Specifying Conventions£©..........................................................................................................25
        ±í4. ´Ì¼¤ºóµÄʱ¼äÑÓ³Ù£¨Table 4: Time Delay Post Challenge£©.........................................................................................................27
        ±í5. ´Ì¼¤²¿·ÖÖеÄ;¾¶ËõÂÔÓTable 5: Route Abbreviations for Challenge Part£©..........................................................................28
        ±í6. ´Ì¼¤µÄÐÔÖÊ£¨Table 6: Nature of Challenge£©.................................................................................................................................29
        ±í7. ÊôÐÔÀàÐÍ£¨Table 7: Kind of Property£©..........................................................................................................................................33
        ±í8. ³ÖÐøÊ±¼äµÄÀà±ð£¨Table 8: Duration Categories£©.........................................................................................................................35
        ±í9. ʱ¼äÌØÕ÷ÐÞÊγɷֵĴúÂ루Table 9: Time Aspect Modifier Codes£©...........................................................................................37
        ±í10. ʵÑéÊÒÊÔÑéÏîÄ¿µÄÌåϵ/Ñù±¾ÀàÐÍ´úÂ루Table 10: Laboratory System/Sample Type Codes£©.................................................38
        ±í11. ³¬Ìåϵ£¨Table 11: Super System£©...............................................................................................................................................39
        ±í12. ±ê³ßÀàÐÍ£¨Table 12: Type of Scale£©...........................................................................................................................................41
        ±í13. ÊÔÑé·½·¨ËõÂÔÓTable 13: Method Abbreviations£©.................................................................................................................42
        ±í14A. ·ÖÀàΪDNA/RNA°ÐÏòÀ©Ôö·½·¨µÄÌØÒìÐÔ·½·¨¾ÙÀý£¨Table 14A: Examples of specific methods that would be classes as target amplified DNA/RNA methods£©.........................................................43
        ±í14B. LOINCÖб»¶¨ÒåΪÐźŷŴ󷽷¨µÄÌØÒìÐÔ·½·¨¾ÙÀý£¨Table 14B. Examples of specific methods that would be defined in LOINC as signal amplification methods£©..............................44
        ±í15. ÅàÑø½á¹û¾ÙÀý£¨Table 15. Example Culture Results£©.................................................................................................................49
        ±í16. Ò©ÎïÃô¸ÐÐÔÊÔÑé·½·¨£¨Table 16: Drug Susceptibility Methods£©...............................................................................................50
        ±í17. ±êʶÒÅ´«»ùÒòȱÏÝλÖõÄÈýÖÖÃüÃû·½·¨£¨Table 17. Three types of nomenclatures for identifying the location of a genetic defect£©.............................................56
        ±í18. µ¥×Öĸ°±»ùËá´úÂëÁÐ±í£¨Table 18. List of single letter amino acid codes£©...............................................................................56
        ±í19. Æù½ñÁÙ´²LOINC²¿·ÖËùº­¸ÇµÄÖ÷Ì⣨Table 19. Subjects covered to date in clinical LOINC£©...............................................64
        ±í20. ÀࣨTable 20: Classes£©.................................................................................................................................................................90
        ±í21. Ìá½»ÎļþʾÀý£¨Table 21: Example submission£©........................................................................................................................95
        ±í22a. Ìá½»ÎļþÖеÄAccessÊý¾Ý¿â×Ö¶ÎÃû£¨Table 22a Access Field Names for Submissions£©.......................................................95
        ±í22b. ¹©RegenstriefÌîдµÄÄÚÈÝ£¨ÌύʱÐè±£³Ö¿ÕÖµµÄ×ֶΣ©£ÛTable 22b Content Added by Regenstrief (Fields left blank in submission)£Ý..................................96
        ±í23. ¿É´òÓ¡ÐÍLOINCÊý¾Ý¿â±¨¸æÖеıí¸ñÁУ¨Table 23: Columns Appearing on Printed Reports£©...................................................116
        LOINC Users¡¯ Guide translated to Simplified Chinese ¡ªJune 1, 2005
        6
        °æÈ¨ÉùÃ÷ÓëÐí¿ÉЭÒ飨Copyright Notice and License£©
        The LOINC® codes, LOINC® database, LOINC® table and related files, and LOINC® Users' Guide are copyright © 1995-2005, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.
        LOINC®´úÂë¡¢LOINC®Êý¾Ý¿â¡¢LOINC®Êý¾Ý¿â±íºÍÏà¹ØÎļþ¼°¡¶LOINC®Óû§Ö¸ÄÏ¡·°æÈ¨ËùÓЩ 1995-2005 Regenstrief Institute, Inc.£¨RegenstriefÑо¿Ôº¹É·ÝÓÐÏÞ¹«Ë¾£©¼°Logical Observation Identifiers Names and Codes (LOINC) Committee£¨¹Û²âÖ¸±ê±êʶ·ûÂß¼­ÃüÃûÓë±àÂëϵͳίԱ»á£¬LOINCίԱ»á£©¡£±£ÁôËùÓÐȨÀû¡£
        The RELMA® program, RELMA® database (but excluding LOINC® codes, and LOINC® table and related files incorporated therein, which are subject to the copyright above) and RELMA® Users' Manual are copyright © 1995-2005, Regenstrief Institute, Inc. All rights reserved.
        RELMA®³ÌÐò¡¢RELMA®Êý¾Ý¿â£¨µ«³ýÍâÆäÖÐËù°üº¬µÄÊÊÓÃÓÚÉÏÊö°æÈ¨µÄLOINC®´úÂë¡¢LOINC®Êý¾Ý¿â±íºÍÏà¹ØÎļþ£©¼°¡¶RELMA®Óû§Êֲᡷ°æÈ¨ËùÓЩ 1995-2005 Regenstrief Institute, Inc.£¨RegenstriefÑо¿Ôº¹É·ÝÓÐÏÞ¹«Ë¾£©¡£±£ÁôËùÓÐȨÀû¡£
        LOINC® and RELMA® are registered United States trademarks of Regenstrief Institute, Inc.
        LOINC®ºÍRELMA®ÊôÓÚRegenstrief Institute, Inc.µÄÃÀ¹ú×¢²áÉ̱ê¡£
        Permission is hereby granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the RELMA® program, RELMA® Users' Manual, RELMA® database, LOINC® codes, LOINC® Users' Guide, LOINC® database, and LOINC® table and related files for any commercial or non-commercial purpose, subject to the following terms and conditions:
        ÏÂÔØµØÖ·
         ÏÂÔØµØÖ·1
        °´×Öĸ¼ìË÷

        ÏÂÔØÐëÖª:
        ´ó²¿·Ý×ÊÔ´ÎÞÐè×¢²á¼´¿ÉÏÂÔØ
        ÐèÒª»ý·ÖµÄ×ÊÔ´ÒªÔÚ»áÔ±ÖÐÐÄ×¢²á»áÔ±²¢Óà »ý·ÖÌåϵÖÐÌáʾµÄ·½·¨×¬È¡»ý·Ö²ÅÄÜÏÂÔØ¡£

        ÃâÔðÉùÃ÷£º
        ËùÓÐ×ÊÔ´Ö»ÄÜÓÃÓڲο¼Ñ§Ï°£¬²»ÄÜÓÃÓÚÈκÎÉÌÒµÓÃ;£¬·ñÔòºó¹û×Ô¸º£¡
        Ö÷Õ¾Ö©Öë³ØÄ£°å£º 成人黄色网 | 国产精品视频第一区二区三区 | 成人网mm视频在线观看 | 久久成人毛片 | 国产精品综合久成人 | 国产成人精品亚洲2020 | 91先生在线观看 | 日韩精品亚洲专区在线观看 | 国产福利在线视频 | 日本免费不卡一区二区 | 日韩欧美三级视频 | 黑人和黑人激情一级毛片 | 黄色免费网址大全 | 日韩精品视频一区二区三区 | 日本一区二区三区精品 | 成年影院在线看网站免费 | 久久www视频| 3344在线看片 | 国产成人亚洲精品一区二区在线看 | 黄色毛片免费网站 | 国产成人在线影院 | 绝对真实偷拍盗摄高清在线视频 | 国产精品天天看 | 精品无人乱码一区二区三区 | 国产成人精品综合在线 | 欧美成人免费sss | 国产精品视频播放 | 成人啪啪免费看 | 日本黄色网址免费 | 成人福利免费在线观看 | 国产成人精品综合在线 | 1024国产基地永久免费 | 91精品免费在线观看 | 成人一级片在线观看 | bbbb成人毛片免费看 | 国产综合精品久久亚洲 | 久久久免费观成人影院 | 日韩毛片最新看 | 国产精品黄网站免费观看 | 国产视频视频 | 奇米影视第四色在线观看 |